PD L1 News and Research

RSS

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Researchers from Japan today reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1-positive unresectable locally advanced non-small cell lung cancer without chemotherapy met its primary endpoint with tolerable adverse reactions.

8 Aug 2022

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

In the initial NADIM trial, neoadjuvant chemoimmunotherapy was shown to be highly effective in patients with resectable stage IIIA non-small cell lung cancer.

8 Aug 2022

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to findings presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Nivolumab approved for combination with fluoropyrimidine- and platinum-based combination chemotherapy

Nivolumab has recently been approved both in combination with fluoropyrimidine- and platinum-based combination chemotherapy and in combination with ipilimumab for the first-line treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with PD-L1 expression of at least one percent. The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in two early benefit assessments whether these two combinations have an added benefit for patients in comparison with chemotherapy alone.

8 Aug 2022

Genetic signatures may help predict immunotherapy response in patients with bladder cancer

Investigators from Cedars-Sinai Cancer have identified genetic signatures that could predict whether tumors in patients with bladder and other cancers will respond to immunotherapy.

3 Aug 2022

TransCode and MD Anderson scientists collaborate to validate therapeutic and diagnostic candidates

The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode's pipeline of RNA-targeted oncology therapeutic and diagnostic candidates.

2 Aug 2022

Cytokine-based cancer immunotherapy: current progress and future prospects

In this interview, News-Medical talks to Dr. Shuang Zhou about cytokine-base cancer immunotherapy, the current state of the field, and future prospects.

From Sino Biological Inc. 18 Jul 2022

Healthy, cancer, and immunosuppressed patients all benefit from COVID boosters

In a recent study posted to the medRxiv* pre-print server, researchers developed a mechanistic mathematical model to predict the course of vaccine-induced immunity in healthy and immunosuppressed patients for the long term, exceeding the time frames for which clinical data is currently available.

5 Jul 2022

Researchers fabricate highly-sensitive SERS probes to detect the PD-L1 biomarker

Recently, a team led by Prof. Huang Qing at the Institute of Intelligent Machines, Hefei Institutes of Physical Science (HFIPS) of Chinese Academy of Sciences (CAS) have reported the fabrication of ultrasensitive biosensors based on Surface-enhanced Raman Spectroscopy (SERS) to detect the cancer metastasis related programmed death ligand (PD-L1) biomarker.

1 Jul 2022

New study looks at the role of beta cells in triggering autoimmunity

Research into the causes of type 1 diabetes often focuses on the autoimmune response, where the immune system destroys pancreatic islet beta cells that produce insulin.

28 Jun 2022

New nanoparticles effectively stopped the growth and spread of ovarian, liver tumors in mice

As they grow, solid tumors surround themselves with a thick, hard-to-penetrate wall of molecular defenses. Getting drugs past that barricade is notoriously difficult.

24 Jun 2022

Lung cancer patients treated with immune checkpoint inhibitors can be safely vaccinated against COVID-19, study says

Cancer patients have received priority status to receive COVID-19 vaccinations but there is limited data regarding the safety and efficacy of the vaccines for patients treated for lung cancer with immune checkpoint inhibitors.

22 Jun 2022

HIV coinfection significantly impacts B cell response to SARS-CoV-2

In recent research posted to the bioRxiv* preprint server, investigators confirmed that human immunodeficiency virus (HIV) co-infection alters B cell reaction in coronavirus disease 2019 (COVID-19).

17 Jun 2022

Liquid biopsy could better predict immunotherapy response in lung cancer patients than tumor biopsy

Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure.

3 Jun 2022

UCLA researchers identify a method to make tumors susceptible to immune attack

One powerful way cancer cells defend against tumor-killing immune cells is to load up their cell surface with a protein known as PD-L1. Now a team of UCLA Jonsson Comprehensive Cancer Center researchers led by Roger S. Lo, MD, PhD, has identified a method to degrade tumor cell-surface PD-L1, thereby making tumors susceptible to immune attack.

31 May 2022

Blood-based biomarker can predict the benefit of immunotherapy to lung cancer patients

A blood-based tumor biomarker can predict the benefit of immunotherapy to patients with non-small cell lung cancer, according to a study published in Nature Medicine.

20 May 2022

First patient dosed in Phase 1 clinical trial evaluating the safety of CF33-hNIS against solid tumors

Imugene Limited, a clinical stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed in a Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors.

18 May 2022

Immunotherapy combined with chemoradiation and surgery could help treat nonmetastatic gastroesophageal cancer

Immunotherapy has transformed treatment for patients with stage 4 metastatic esophageal and gastric cancers. In patients with these malignancies, immunotherapy has been shown to prolong survival when patients' tumors exhibit a high expression of an immune-related protein called PD-L1.

16 May 2022

Immunotherapy after bladder cancer surgery helps reduce cancer recurrence

Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high risk for recurrence, according to clinical trial results presented at the American Urological Association annual meeting in May.

15 May 2022

Stem cell therapy prevents type 1 diabetes induced by anti-cancer drugs

Immune checkpoint inhibitors are widely used to treat a variety of cancers; however, one serious side effect is the onset of type 1 diabetes.

6 May 2022

PD L1 News and Research

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

Nivolumab approved for combination with fluoropyrimidine- and platinum-based combination chemotherapy

Genetic signatures may help predict immunotherapy response in patients with bladder cancer

TransCode and MD Anderson scientists collaborate to validate therapeutic and diagnostic candidates

Cytokine-based cancer immunotherapy: current progress and future prospects

Healthy, cancer, and immunosuppressed patients all benefit from COVID boosters

Researchers fabricate highly-sensitive SERS probes to detect the PD-L1 biomarker

New study looks at the role of beta cells in triggering autoimmunity

New nanoparticles effectively stopped the growth and spread of ovarian, liver tumors in mice

Lung cancer patients treated with immune checkpoint inhibitors can be safely vaccinated against COVID-19, study says

HIV coinfection significantly impacts B cell response to SARS-CoV-2

Liquid biopsy could better predict immunotherapy response in lung cancer patients than tumor biopsy

UCLA researchers identify a method to make tumors susceptible to immune attack

Blood-based biomarker can predict the benefit of immunotherapy to lung cancer patients

First patient dosed in Phase 1 clinical trial evaluating the safety of CF33-hNIS against solid tumors

Immunotherapy combined with chemoradiation and surgery could help treat nonmetastatic gastroesophageal cancer

Immunotherapy after bladder cancer surgery helps reduce cancer recurrence

Stem cell therapy prevents type 1 diabetes induced by anti-cancer drugs

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News